Pharmaceutical Sciences and Drug Design · 2022 · 18 citations · 7 references
PharmacyMedicinal ChemistryPharmacologyDrug DesignDrug DiscoveryMass Spectrometric AnalysisBioanalytical Method ValidationTyrosine Kinase InhibitorsUltraviolet SpectroscopyUltraviolet-visible SpectroscopyJak Inhibitor TherapyJanus Kinase Inhibitor TherapyRheumatoid Arthritis PharmacotherapySupplemental Oxygen TherapyUv-visible Quantitative Analysis
Baricitinib is a novel therapeutic agent recently approved for the treatment of moderate to severe rheumatoid arthritis, severe alopecia areata, and since 2022, COVID-19 in hospitalized adults requiring supplemental oxygen. This drug acts as a selective inhibitor of Janus kinase 1 and 2. This study aimed to establish and validate a stability-indicating UV spectroscopic method for the measurement of baricitinib in both bulk and formulated forms. A straightforward, precise, and cost-effective UV m
7
Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19
André C. Kalil, Thomas F. Patterson, Aneesh K. Mehta et al. · New England Journal of Medicine · 2020 · 1.9K citations · Full text
Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis
Peter C. Taylor, Edward Keystone, Désirée van der Heijde et al. · New England Journal of Medicine · 2017 · 951 citations · Full text